Baillie Gifford & Co
ACET icon

Baillie Gifford & Co’s Adicet Bio ACET Stock Holding History

Baillie Gifford & Co’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,352
Closed -$441K – 290
2023
Q2 		$441K Hold
11,352
– – ﹤0.01% 276
2023
Q1 		$1.05M Hold
11,352
– – ﹤0.01% 265
2022
Q4 		$1.62M Hold
11,352
– – ﹤0.01% 263
2022
Q3 		$2.58M Hold
11,352
– – ﹤0.01% 260
2022
Q2 		$2.65M Hold
11,352
– – ﹤0.01% 260
2022
Q1 		$3.63M Hold
11,352
– – ﹤0.01% 259
2021
Q4 		$3.18M Hold
11,352
– – ﹤0.01% 264
2021
Q3 		$1.42M Hold
11,352
– – ﹤0.01% 268
2021
Q2 		$1.87M Hold
11,352
– – ﹤0.01% 264
2021
Q1 		$2.38M Hold
11,352
– – ﹤0.01% 255
2020
Q4 		$2.55M Hold
11,352
– – ﹤0.01% 241
2020
Q3 		$2.16M Hold
11,352
– – ﹤0.01% 231
2020
Q2 		$2.73M Hold
11,352
– – ﹤0.01% 215
2020
Q1 		$1.31M Hold
11,352
– – ﹤0.01% 199
2019
Q4 		$1.9M Hold
11,352
– – ﹤0.01% 201
2019
Q3 		$11.2M Hold
11,352
– – 0.01% 175
2019
Q2 		$13M Hold
11,352
– – 0.01% 181
2019
Q1 		$8.67M Buy
11,352
+2,570
+29% +$2.34M 0.01% 189
2018
Q4 		$8.48M Hold
8,782
– – 0.01% 188
2018
Q3 		$14.9M Buy
8,782
+834
+10% +$1.09M 0.02% 169
2018
Q2 		$8.14M Buy
7,948
+3,037
+62% +$3.27M 0.01% 182
2018
Q1 		$5.27M Buy
+4,911
New +$9.01M 0.01% 190

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Baillie Gifford & Co's ACET Position: Q3 2023 in Review

Baillie Gifford & Co sold out of Adicet Bio (ACET) in Q3 2023, closing a stake of 11,352 shares — an estimated $441K sold.

Baillie Gifford & Co first reported a position in ACET in Q1 2018 and held it in 22 quarters. The position peaked at $14.9M in Q3 2018. 83 funds tracked by Wall St. Rank hold ACET as of Q3 2023.

  • Baillie Gifford & Co reported no remaining Adicet Bio position as of Q3 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 11,352 Adicet Bio shares in Q3 2023, an estimated $441K.
  • Baillie Gifford & Co first reported a position in Adicet Bio in Q1 2018 and held it in 22 quarters.
  • Baillie Gifford & Co's Adicet Bio position peaked at $14.9M in Q3 2018.
  • 83 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2023.

Based on Baillie Gifford & Co's 13F filing for Q3 2023, filed 13 Nov 2023.